drugset
drugset / Trial / NCT01195636

A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

NCT01195636 ↗

Phase 2 Completed 70 enrolled Xenon Pharmaceuticals Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this trial is to determine if XPF-002 is safe and effective for the treatment of pain in subjects with Postherpetic Neuralgia

Timeline

Start
2010-08
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject funapide Small molecule 8 % Topical

Indications

postherpetic neuralgia